4SC AG announced the completion of its capital increase resolved on 12 June 2017 to continue to advance its drug development programs for resminostat, 4SC-202 and 4SC-208.
by eazee-designstudio
Sponsored by the National Institutes of Health, Themis Bioscience started a Phase II trial of its Chikungunya vaccine on a candidate in the U.S.
Rigontec today announced the dosing of the first patient in a phase I/II study with intratumoral/intralesional administration of its lead compound RGT100 in solid tumors and lymphoma. In addition, Rigontec appoints industry veteran Prof. Eugen Leo as Chief Medical Officer.
The Supervisory Board of AYOXXA announces that following his initial assumption of the duties of CEO in October, Rodney Turner will continue to lead the company on a permanent basis
invendo medical Announces CE Mark for the invendoscope(TM) SC200, The World's First Sterile, Single-Use Endoscope For Colonoscopies
Chiesi Enhances Asthma Portfolio with Acquisition of Atopix Therapeutics
Uromems closes €14m financing to develop its smart artificial urinary sphincter to market
Rigontec Appoints Dr. Jörg Vollmer as Chief Scientific Officer
Amgen and Immatics Enter Strategic Collaboration to Develop Novel Bispecific Cancer Immunotherapies
The supervisory board of AYOXXA announces that Mr. Rodney Turner has assumed duties as interim CEO
